Richard B. Resnick, MD
Acknowledgments: The author thanks Charles O'Keeffe and Elaine Resnick, MSW, for editorial suggestions.
Grant Support: In part by a research grant from the National Institute of Drug Abuse (RO1DA10728).
Resnick RB. Food and Drug Administration Approval of BuprenorphineNaloxone for Office Treatment of Addiction. Ann Intern Med. ;138:360. doi: 10.7326/0003-4819-138-4-200302180-00027
Download citation file:
Published: Ann Intern Med. 2003;138(4):360.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use